Macular Degeneration Trial, Recruiting NCT05959005 Sponsor: University of Utah Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT05959005
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male or female, aged 50 or older, of any ethnicity
  • Your eye being studied has at least one early area of damage to the light-sensitive layer at the back of the eye (called the retinal pigment epithelium), either partial or complete, as detected by a special eye scan — and if complete, the damaged area is no larger than half the size of the optic disc (a small specific measurement used in eye care) (confirm with trial site)
  • Your eye is clear enough, your pupil can be dilated enough, and you can focus well enough to allow good-quality eye imaging and vision testing
  • You are able to follow the study schedule and attend all required visits

Who may not be able to join:

  • Your study eye shows signs of fluid buildup, leaking, or bleeding at the back of the eye
  • The area of complete damage at the back of your study eye is larger than half a disc area at the start of the study
  • You have ever had treatment for a leaking or "wet" form of abnormal blood vessel growth in your study eye
  • You have any eye condition other than age-related macular degeneration (AMD) in your study eye, including uncontrolled glaucoma or eye inflammation
  • You have previously had laser treatment or a related light-based therapy for AMD in your study eye
  • You had cataract surgery in your study eye within the last three months, or a laser eye capsule procedure within the last two weeks
  • You are currently taking part in, or have previously taken part in, a clinical trial testing a drug or supplement for AMD (except trials involving only vitamins and minerals)
  • You are currently taking part in, or recently finished (within the last three months), a clinical trial testing a drug or supplement for any condition other than AMD
  • You have another eye condition in your study eye that, in the doctor's opinion, is likely to need treatment during the study or could cause significant vision loss if left untreated
  • You have a condition that, in the doctor's opinion, would make it difficult for you to attend all study appointments regularly (for example, severe memory problems or substance dependency)
  • You have a serious ongoing health condition that is not well controlled, such as heart, lung, kidney, liver, or neurological disease (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Monika Fleckenstein, University of Utah

Phone: 801 585 1890

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 October 2023
Est. completion
30 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in geographic atrophy (GA) lesion size

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov